Goslinga H, Eijzenbach V, Heuvelmans J H, van de Nes J C, Kurk R M, Bezemer P D
Sint Lucas Ziekenhuis, afd. Anesthesiologie en Intensive Care, Amsterdam.
Ned Tijdschr Geneeskd. 1992 Dec 5;136(49):2422-8.
To determine the effect of normovolaemic haemodilution in patients after a cerebrovascular accident.
Prospective, randomized clinical trial.
St Lucas Hospital, Amsterdam.
Normovolaemic haemodilution was achieved by means of bloodletting and administration of a 20% solution of albumin plus crystalline infusion fluids under haemodynamic and rheological monitoring during the acute phase of the cerebral infarction. All patients were subjected to general intensive care and monitoring with a pulmonary artery catheter. This custom-tailored fluid therapy was guided by a pulmonary wedge pressure of 12 mm Hg (SD 3) and a haematocrit (Ht) of 0.32 l/l (SD 0.02). The control group only received individually dosed rehydration with crystalline infusion fluids. Endpoints of the study after 3 months were mortality and dependence/independence concerning everyday functioning.
The results in the total haemodilution group and the control group did not differ significantly. However, in the subgroup with normal Ht (< 0.45 l/l; n = 201) there was a significant reduction (p < 0.05) of the mortality after 3 months (27% and 16%, respectively) and an increase of independence at home (35% and 48%, respectively) due to a reduction of the viscosity by means of haemodilution with albumin (a specific viscosity effect in the normovolaemic group). In the control group with raised Ht (dehydration; Ht > or = 0.45 l/l; n = 50) there was a significant decrease (p < 0.005) of the mortality after 3 months (27% and 8%, respectively) and an increase of independence at home (35% and 59%, respectively) compared with the control group with normal Ht without signs of dehydration (Ht < 0.045 l/l; n = 102), due to rehydration exclusively with crystalline infusion fluids (a specific rehydration effect in the dehydrated group).
In cerebrovascular accident patients haemodilution should be adjusted individually; in normovolaemic patients haemodilution should be carried out with an albumin solution; the higher the Ht, the more rehydration with crystalline infusion fluids is to be carried out.
确定等容血液稀释对脑血管意外患者的影响。
前瞻性随机临床试验。
阿姆斯特丹圣卢卡斯医院。
在脑梗死急性期,通过放血并在血流动力学和流变学监测下给予20%白蛋白溶液加晶体输液来实现等容血液稀释。所有患者均接受常规重症监护并用肺动脉导管进行监测。这种量身定制的液体疗法以12毫米汞柱(标准差3)的肺楔压和0.32升/升(标准差0.02)的血细胞比容为指导。对照组仅接受个体化剂量的晶体输液补液。3个月后的研究终点为死亡率以及日常功能方面的依赖/独立情况。
全血液稀释组和对照组的结果无显著差异。然而,在血细胞比容正常(<0.45升/升;n = 201)的亚组中,3个月后死亡率显著降低(p<0.05)(分别为27%和16%),且由于用白蛋白进行血液稀释降低了粘度(等容组的特定粘度效应),在家中的独立能力有所提高(分别为35%和48%)。在血细胞比容升高(脱水;血细胞比容≥0.45升/升;n = 50)的对照组中,与无脱水迹象(血细胞比容<0.45升/升;n = 102)的血细胞比容正常的对照组相比,3个月后死亡率显著降低(p<0.005)(分别为27%和8%),在家中的独立能力有所提高(分别为35%和59%),这是由于仅用晶体输液进行补液(脱水组的特定补液效应)。
对于脑血管意外患者,血液稀释应个体化调整;对等容患者应使用白蛋白溶液进行血液稀释;血细胞比容越高,就越应使用晶体输液进行补液。